BioPharmSignal logoBioPharmSignal

Biotech News

SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

SELLAS Life Sciences Group, Inc. (SLS)SELLAS Life Sciences Group, Inc.Clinical readout

SLS (SLS) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is sls.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

SLSSELLAS Life Sciences Group, Inc.2026-11-04 14:00 EST

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

SLSSELLAS Life Sciences Group, Inc.2026-10-28 12:35 EST

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

NRIXNurix Therapeutics2026-11-05 12:00 EST

Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition

BMYBMYBristol-Myers Squibb Company2026-10-08 10:59 EST

Bristol Myers Squibb Announces ZENBEXUS (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

LYELLyell Immunopharma2026-11-04 14:01 EST

Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma

GERNGeron2026-10-28 12:00 EST

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

CGEMCullinan Therapeutics, Inc.2026-10-08 11:00 EST

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

BMYBMYBristol-Myers Squibb Company2026-11-06 21:00 EST

Bristol Myers Squibb Presents 56-Week Phase 3 Data in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) for Camzyos (mavacamten) at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions

ERASErasca2026-11-04 13:30 EST

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

FATEFate Therapeutics2026-10-26 11:00 EST

Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026

View all latest news

SELLAS Life Sciences Group, Inc.

Late-Stage Oncology Company SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor. Galinpepimut-S Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer...

Recent company news

SLSSELLAS Life Sciences Group, Inc.2026-11-04 14:00 EST

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

SLSSELLAS Life Sciences Group, Inc.2026-10-28 12:35 EST

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

SLSSELLAS Life Sciences Group, Inc.2026-09-25 17:00 EST

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

SLSSELLAS Life Sciences Group, Inc.2026-09-25 17:00 EST

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

SLSSELLAS Life Sciences Group, Inc.2026-09-02 12:30 EST

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

Stock data

Close
7.88 USD
Market cap
1.55B USD
Exchange
NASDAQ
Sector
Life Science Tools
Location
United States